ADMA Biologics Inc (NASDAQ:ADMA) Releases Earnings Results
ADMA Biologics Inc (NASDAQ:ADMA) posted its earnings results on Friday. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.29, Bloomberg Earnings reports. The business had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $3.52 million.
ADMA Biologics (NASDAQ:ADMA) traded up 1.03% during mid-day trading on Friday, hitting $2.94. 36,784 shares of the company’s stock were exchanged. ADMA Biologics has a 12 month low of $2.76 and a 12 month high of $7.70. The stock’s market cap is $37.88 million. The stock’s 50 day moving average price is $3.47 and its 200-day moving average price is $4.19.
A number of analysts have weighed in on ADMA shares. Maxim Group set a $13.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a research note on Monday, May 15th. ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Stock Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related stocks with our FREE daily email newsletter.